This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-05 and is reviewed periodically as new material appears.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Lignin is a pervasive natural macromolecule. It comprises about a third of the mass of trees. lignin arises by crosslinking. Related to lignin are polyphenols, which consist of a branched structure of multiple phenolic subunits. They can perform structural roles (e.g. lignin) as well as roles as secondary metabolites involved in signalling, pigmentation and defense.
p A + q B ⇌ ApBq The study of these complexes is important for supramolecular chemistry and molecular recognition. The objective of these studies is often to find systems with a high binding selectivity of a host (receptor) for a particular target molecule or ion, the guest or ligand. An application is the development of chemical sensors. Finding a drug which either blocks a receptor, an antagonist which forms a strong complex the receptor, or activate it, an agonist, is an important pathway to drug discovery.
=== Control strategies === There is no known method of eradication or control for invasive Cercopagis pengoi. Containing the spread to new areas is the only form of management. Stricter ballast water regulations and awareness would prevent the spread. The C. pengoi invasion of the Great Lakes occurred after the United States passed a regulation requiring ships exchange freshwater ballast water with ocean water to kill off potential invaders. This means that either the resting eggs remain viable even after boats filled with ballast water switch out their ballast water in the ocean, or the required ballast water regulations are not being followed, or the species was brought into the Great Lakes in no-ballast-on-board (NOBOB) vessels (the most like possibility). NOBOB vessels carry only residual water (<50000L) but were not required to exchange ballast water at the time of Cercopagis' invasion. Locally C. pengoi spread can be limited by only releasing bait or bait water into the water body where the bait was originally collected. Boat owners should wash their boats and equipment with high pressure and hot water (above 40 °C) to limit the spread of adult C. pengoi. Alternatively boats and equipment should be allowed to dry for at least five days before moving to another body of water.
Wellcome (Chinese: 惠康; Jyutping: wai6 hong1; pinyin: Huìkāng) is a supermarket chain owned by British conglomerate Jardine Matheson Holdings via its DFI Retail Group subsidiary. The Wellcome supermarket chain is one of the two largest supermarket chains in Hong Kong, the other being ParknShop. DFI formerly operated supermarkets in the Philippines and Taiwan (Chinese: 頂好; pinyin: Dǐnghǎo) under the Wellcome name, and has various other supermarkets around Asia including Market Place, Cold Storage, Hero and Giant.
Sources: en.wikipedia.org
=== Chromatography === Chromatographic methods of removing viruses are great for purifying the protein and are also effective against all types of viruses, but the level of virus removal is dependent on the column composition and the reagents that are used in the process. The effectiveness of this process can vary greatly between viruses and its efficiency can change based on the buffer used. Sanitation between batches is also a concern when performing this procedure. Membrane chromatography is increasingly popular for virus purification and removal.
=== Early ventures === Johnson launched three startups between 1999 and 2003. The first one sold cell phones and helped pay his way through Brigham Young University. Johnson hired other university students to sell service plans and cell phones; Johnson earned about a $300 commission on each sale. He also started two other businesses. Inquist, a VoIP company Johnson co-founded with three other partners, combined features of Vonage and Skype. It ended operations in 2001. After that, he joined his brother and another partner on a $70 million real estate project in 2001. The project did not meet its sales goals.
ALK-positive ALCL occurs mostly but not exclusively in children and young adults and is slightly more common in males. Most individuals present with stage III or IV (i.e. advanced) disease. They evidence systemic symptoms including B symptoms such as fever, night sweats, and weight loss in 75% of cases; lymph node enlargement (90%) including those in the mediastinum (36%); and lymphomatous lesions in the skin (26%), bone (14%), soft tissues (15%), lung (12%), and/or liver (8%). Tumor cells are found in the bone marrow in up to 40% of the cases when immunohistochemical analysis is performed. Involvement of the central nervous system or a leukemia-like circulation of malignant cells in the blood occurs only very rarely. Most patients, including up to 90% of young children and adolescents, have circulating autoantibodies directed against the ALK fusion protein expressed by their tumor cells.
Bohrium is a synthetic chemical element; it has symbol Bh and atomic number 107. It is named after Danish physicist Niels Bohr. As a synthetic element, it can be created in particle accelerators but is not found in nature. All known isotopes of bohrium are highly radioactive; the most stable known isotope is 270Bh with a half-life of approximately 2.4 minutes, though the unconfirmed 278Bh may have a longer half-life of about 11.5 minutes. In the periodic table, it is a transactinide element in the d-block. It is a member of the 7th period and belongs to the group 7 elements as the fifth member of the 6d series of transition metals. Chemistry experiments have confirmed that bohrium behaves as the heavier homologue to rhenium in group 7. The chemical properties of bohrium are characterized only partly, but they compare well with the chemistry of the other group 7 elements.
[Citation Needed] All of the above have been, owing to their somewhat sophisticated yet straightforward synthesis from pharmaceutical opioids, consistently if in vanishingly small quantities since at least the 1960s by law enforcement around the world as the results of clandestine synthesis, and acetylmorphone itself was banned by the League of Nations in 1930 to prevent its use as a legal heroin substitute.[Citation Needed][Relevance] Therefore, all or most of this group and its hydromorphone analogues along with some others more closely related to heroin such as acetylpropionylmorphine were the first designer drugs in the 1920s.
Sources: en.wikipedia.org
== First Ministry == On 29 June 1998, a full ministry of 18 cabinet ministers and 4 parliamentary secretaries was sworn in. It served until the reconstitution of the Ministry on 22 February 2001 following the 2001 election. The list below is ordered by decreasing seniority within the Cabinet, as indicated by the Government Gazette and the Hansard index.
==== GnRH-associated peptide ==== GnRH-associated peptide (GAP), a 56-amino-acid peptide cleaved from the GnRH precursor, was shown in 1985 to inhibit prolactin secretion in rat pituitary cultures at a potency comparable to dopamine. Its physiological significance in vivo remains uncertain, as results have varied across species.
== Management == Numerous treatment options are used in obstructive sleep apnea. Avoiding alcohol and smoking is recommended, as is avoiding medications that relax the central nervous system (for example, sedatives and muscle relaxants). Weight loss is recommended in those who are overweight. Continuous positive airway pressure (CPAP) and mandibular advancement devices are often used and found to be equally effective. Physical training, even without weight loss, improves sleep apnea. There is insufficient evidence to support widespread use of medications. In selected patients, e.g., with tonsillar hyperplasia, tonsillectomy is recommended. In patients failing CPAP and oral appliances, surgical treatment with conservative uvulopalatopharyngoplasty (UPPP) as salvage surgery is recommended. UPPP has a positive effect on nocturnal respiration and excessive daytime sleepiness.
=== 1994–1999: Rise and critical acclaim === Carrey played the lead role in Ace Ventura: Pet Detective which was released in February 1994 and went on to gross $72 million in the United States and Canada. Following its success and before the release of his next film, The Mask, which was anticipated to be another hit, Morgan Creek Productions paid him $5 million to reprise his role as Ace Ventura and New Line Cinema offered him $7 million to make a sequel to The Mask and paid him $7 million to appear in Dumb and Dumber, a nearly tenfold increase on his salary for Ace Ventura. The Mask, released in July 1994, grossed $351 million worldwide, and Dumb and Dumber, released in December 1994, was another commercial success, grossing over $270 million worldwide. Carrey received his first Golden Globe Award nomination for Best Actor for his work in The Mask and was voted second on Quigley's Top Ten Money Making Stars Poll, behind Tom Hanks. Carrey portrayed the Batman villain the Riddler in the Joel Schumacher-directed superhero film Batman Forever (1995). The film received mixed reviews, but was a box office success. He reprised his role as Ace Ventura in Ace Ventura: When Nature Calls which was also released in 1995. Like the original film, it was well received by the public, but poorly received by critics. It was a huge box-office success, earning $212 million worldwide in addition to breaking records, with a $40 million opening weekend. Carrey became the first comic actor to be paid an upfront salary of $20 million for his next film, The Cable Guy (1996).
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.